EP0984692A4 - Novel angiogenesis inhibitors - Google Patents

Novel angiogenesis inhibitors

Info

Publication number
EP0984692A4
EP0984692A4 EP98923719A EP98923719A EP0984692A4 EP 0984692 A4 EP0984692 A4 EP 0984692A4 EP 98923719 A EP98923719 A EP 98923719A EP 98923719 A EP98923719 A EP 98923719A EP 0984692 A4 EP0984692 A4 EP 0984692A4
Authority
EP
European Patent Office
Prior art keywords
angiogenesis inhibitors
novel angiogenesis
novel
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98923719A
Other languages
German (de)
French (fr)
Other versions
EP0984692A1 (en
Inventor
Mark T Bilodeau
Randall W Hungate
Richard L Kendall
Ruth Rutledge
Kenneth A Thomas Jr
Robert Rubino
Mark E Fraley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US4807697P priority Critical
Priority to US48076P priority
Priority to GB9800681 priority
Priority to GBGB9800681.0A priority patent/GB9800681D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to PCT/US1998/010590 priority patent/WO1998054093A1/en
Publication of EP0984692A1 publication Critical patent/EP0984692A1/en
Publication of EP0984692A4 publication Critical patent/EP0984692A4/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
EP98923719A 1997-05-30 1998-05-26 Novel angiogenesis inhibitors Withdrawn EP0984692A4 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US4807697P true 1997-05-30 1997-05-30
US48076P 1997-05-30
GB9800681 1998-01-14
GBGB9800681.0A GB9800681D0 (en) 1998-01-14 1998-01-14 Novel angiogenesis inhibitors
PCT/US1998/010590 WO1998054093A1 (en) 1997-05-30 1998-05-26 Novel angiogenesis inhibitors

Publications (2)

Publication Number Publication Date
EP0984692A1 EP0984692A1 (en) 2000-03-15
EP0984692A4 true EP0984692A4 (en) 2001-02-21

Family

ID=26312935

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98923719A Withdrawn EP0984692A4 (en) 1997-05-30 1998-05-26 Novel angiogenesis inhibitors

Country Status (5)

Country Link
EP (1) EP0984692A4 (en)
JP (1) JP2002501532A (en)
AU (1) AU734009B2 (en)
CA (1) CA2291709A1 (en)
WO (1) WO1998054093A1 (en)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002523498A (en) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ Pyrimidine compounds
WO2000012485A1 (en) 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
JP2002523459A (en) * 1998-08-31 2002-07-30 メルク エンド カムパニー インコーポレーテッド New angiogenesis inhibitor
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6265403B1 (en) * 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
JP3893026B2 (en) 1999-02-10 2007-03-14 アストラゼネカ アクチボラグ Quinazoline derivatives as angiogenesis inhibitors
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
KR100733949B1 (en) 1999-03-26 2007-07-02 마이크로소프트 코포레이션 Lossless adaptive encoding of finite alphabet data
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
ME00328B (en) 1999-11-11 2011-05-10 Osi Pharmaceuticals Llc Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
MXPA02012943A (en) 2000-08-09 2003-05-15 Astrazeneca Ab Cinnoline compounds.
JP2004505964A (en) 2000-08-09 2004-02-26 アストラゼネカ アクチボラグ Quinoline derivatives having Vegf inhibitory activity
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
PL214667B1 (en) 2000-12-21 2013-08-30 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators
PT1399483E (en) 2001-01-05 2010-07-20 Pfizer Antibodies to insulin-like growth factor i receptor
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc CD40 antibodies
WO2003051886A1 (en) * 2001-12-17 2003-06-26 Smithkline Beecham Corporation Pyrazolopyridazine derivatives
KR101093345B1 (en) 2002-02-01 2011-12-14 아스트라제네카 아베 Quinazoline compounds
JP2005527511A (en) 2002-03-01 2005-09-15 ファイザー インコーポレイテッド Indolyl useful thienopyridines as anti-angiogenic agents - urea derivatives and their use
JP2005524672A (en) 2002-03-09 2005-08-18 アストラゼネカ アクチボラグ Imidazolyl substituted pyrimidine derivatives having Cdk inhibitory activity
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EP1504004B1 (en) 2002-05-10 2007-06-27 SmithKline Beecham Corporation Substituted pyrazolopyrimidines
US7449488B2 (en) * 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
MXPA04011637A (en) 2002-06-14 2005-03-07 Pfizer Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use.
CZ293015B6 (en) * 2002-10-25 2004-01-14 Léčiva, A.S. Process for preparing N-ethyl-N-[3-(3-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-phenyl]-acetamide (zaleplon)
EA008501B1 (en) 2002-12-19 2007-06-29 Пфайзер Инк. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
KR101106905B1 (en) 2003-02-26 2012-01-25 수젠, 인크. Aminoheteroaryl compounds as protein kinase inhibitors
JP4564485B2 (en) 2003-02-28 2010-10-20 帝人ファーマ株式会社 Pyrazolo [1,5-a] pyrimidine derivatives
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0314262D0 (en) 2003-06-19 2003-07-23 Univ Nottingham Trent Novel compounds and methods of using the same
DE602004017479D1 (en) 2003-08-29 2008-12-11 Pfizer As a new antiangiogenic agent suitable thienopyridinphenylacetamide and derivatives thereof
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co Antibodies to m-csf
DE10356579A1 (en) * 2003-12-04 2005-07-07 Merck Patent Gmbh amine derivatives
WO2005063756A1 (en) * 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
BRPI0418102A (en) 2003-12-23 2007-04-27 Pfizer quinoline derivatives
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
CA2578066C (en) 2004-08-26 2011-10-11 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
WO2006033795A2 (en) * 2004-09-17 2006-03-30 Wyeth Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth
AT482213T (en) * 2004-11-04 2010-10-15 Vertex Pharma As inhibitors of protein kinases suitable pyrazoloä1,5-aüpyrimidine
EP1863848A4 (en) 2005-03-31 2009-09-23 Agensys Inc Antibodies and related molecules that bind to 161p2f10b proteins
WO2006114704A2 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
KR101536487B1 (en) 2005-09-07 2015-07-13 암젠 프레몬트 인코포레이티드 Human monoclonal antibodies to activin receptor-like kinase-1
ES2374450T3 (en) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Predictive biomarkers of anti-cancer response to receptor kinase inhibitors of growth factor similar to insulin 1.
CN101277956A (en) 2005-09-30 2008-10-01 阿斯利康(瑞典)有限公司 Imidazo [1,2-A] pyridine having anti-cell-proliferation activity
KR20080063806A (en) 2005-10-06 2008-07-07 쉐링 코포레이션 Pyrazolopyrimidines as protein kinase inhibitors
EP2021338A1 (en) 2006-05-09 2009-02-11 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
EP1900739A1 (en) * 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
WO2008033408A2 (en) * 2006-09-12 2008-03-20 The General Hospital Corporation Methods for identifying compounds that modulate cell signaling and methods employing such compounds
WO2008058126A2 (en) * 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
MX2009006704A (en) 2006-12-22 2009-06-30 Astex Therapeutics Ltd New compounds.
CN101679408B (en) * 2006-12-22 2016-04-27 Astex治疗学有限公司 Bicyclic heterocyclic compounds as inhibitors fgfr
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
WO2009014620A1 (en) 2007-07-20 2009-01-29 Merck & Co., Inc. Pyrazolo[1,5-a]pyrimidine derivatives
EP2185574B1 (en) 2007-09-07 2013-05-08 Agensys, Inc. Antibodies and related molecules that bind to 24p4c12 proteins
JP5372763B2 (en) * 2007-09-28 2013-12-18 協和発酵キリン株式会社 Prevention and / or therapeutic agent for skin diseases
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
CA2708361C (en) 2007-12-14 2016-06-07 F. Hoffmann-La Roche Ag Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives
JP5587206B2 (en) 2007-12-19 2014-09-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Useful pyrazolo a JAK2 inhibitor [1,5-a] pyrimidine
US8507501B2 (en) * 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2010045495A2 (en) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
AU2010210986A1 (en) 2009-02-09 2011-08-25 Supergen, Inc. Pyrrolopyrimidinyl Axl kinase inhibitors
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
JP2012519170A (en) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー insitu method for monitoring the emt status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20100222381A1 (en) 2009-02-27 2010-09-02 Hariprasad Vankayalapati Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
AU2010273585B2 (en) 2009-07-13 2015-04-23 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
EP2459191A1 (en) 2009-07-31 2012-06-06 OSI Pharmaceuticals, LLC Mtor inhibitor and angiogenesis inhibitor combination therapy
US20120157471A1 (en) 2009-09-01 2012-06-21 Pfizer Inc. Benzimidazole derivatives
JP2013504595A (en) 2009-09-11 2013-02-07 ジェネンテック, インコーポレイテッド The method for identifying patients likely response to anticancer drugs has increased
BR112012005670A2 (en) 2009-09-17 2017-01-10 Hoffmann La Roche 'Method of identifying a cancer patient who may benefit from therapy antiagiogênica, a method for predicting the responsiveness of a cancer patient to anti-angiogenic therapy, use of a anto- VEGF antibody to improve the effect of treatment of a suffering from cancer patients, method or use, kit useful for performing the method, use of a protein or USOM kit useful for performing the method, use of a protein or oligonucleotide or polinecleotídeo matrix to determine the level of bFGF expression in a method and use or kit
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
SG182533A1 (en) 2010-02-12 2012-08-30 Pfizer Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
ES2585287T3 (en) 2010-03-05 2016-10-04 Kyowa Hakko Kirin Co., Ltd. Pyrazolopyrimidine derivative
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
EP3135692B8 (en) 2010-06-16 2019-03-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Antibodies to endoplasmin and their use
JP2013534307A (en) 2010-07-19 2013-09-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Method of identifying an increased patient response potential for anti-cancer therapy
CN103109189A (en) 2010-07-19 2013-05-15 霍夫曼-拉罗奇有限公司 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
US20130177500A1 (en) 2010-07-23 2013-07-11 Trustee Of Boston University Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
AU2011310713A1 (en) * 2010-09-27 2013-04-11 Proximagen Ltd 7-hydroxy-pyrazolo[1,5-a] pyrimidine compounds and their use as CCR2 receptor antagonists
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
WO2012052948A1 (en) 2010-10-20 2012-04-26 Pfizer Inc. Pyridine- 2- derivatives as smoothened receptor modulators
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
US8748435B2 (en) 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
CA3019531A1 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
WO2013013188A1 (en) 2011-07-21 2013-01-24 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
CN104023729A (en) 2011-09-02 2014-09-03 协和发酵麒麟株式会社 Chemokine receptor activity regulator
BR112014006840A2 (en) 2011-09-22 2017-04-04 Pfizer pyrrolopyrimidine and purine derivatives
ES2654160T3 (en) 2011-10-04 2018-02-12 Igem Therapeutics Limited IgE antibodies anti-HMW-MAA
US20140286959A1 (en) 2011-11-08 2014-09-25 Pfizer Inc. Methods of Treating Inflammatory Disorders Using Anti-M-CSF Antibodies
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN107501274A (en) 2012-12-07 2017-12-22 沃泰克斯药物股份有限公司 Compounds useful as inhibitors of ATR kinase
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US9567643B2 (en) 2013-10-04 2017-02-14 Aptose Biosciences Inc. Compositions and methods for treating cancers
AU2014351433B2 (en) 2013-11-21 2017-08-24 Pfizer Inc. 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
AU2014360380B2 (en) 2013-12-06 2019-03-21 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
CA2947130C (en) 2014-04-30 2018-10-02 Pfizer Inc. Cycloalkyl-linked diheterocycle derivatives
CN107074863A (en) 2014-06-05 2017-08-18 沃泰克斯药物股份有限公司 Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
CN106999578A (en) 2014-07-31 2017-08-01 美国政府(由卫生和人类服务部的部长所代表) Human monoclonal antibodies against epha4 and their use
EP3233829A1 (en) 2014-12-18 2017-10-25 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
EP3383375A1 (en) 2015-12-03 2018-10-10 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
CN106632260B (en) * 2016-09-29 2019-04-26 上海天慈生物谷生物工程有限公司 A kind of preparation method of small molecule kinase inhibitors
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029109A1 (en) * 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as crf receptor antagonists
EP0795555A1 (en) * 1995-09-28 1997-09-17 Otsuka Pharmaceutical Factory, Inc. Analgesics

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0795555A1 (en) * 1995-09-28 1997-09-17 Otsuka Pharmaceutical Factory, Inc. Analgesics
WO1997029109A1 (en) * 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as crf receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIRKPATRICK W E ET AL: "3-HALO-5,7-DIMETHYLPYRAZOLO U1,5-APYRIMIDINES, A NONBENZODIAZEPINOID CLASS OF ANTIANXIETY AGENTS DEVOID OF POTENTIATION OF CENTRAL NERVOUS SYSTEM DEPRESSANT EFFECTS OF ETHANOL OR BARBITURATES", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 20, no. 3, 1 March 1977 (1977-03-01), pages 386 - 393, XP000670076, ISSN: 0022-2623 *
See also references of WO9854093A1 *

Also Published As

Publication number Publication date
CA2291709A1 (en) 1998-12-03
WO1998054093A1 (en) 1998-12-03
EP0984692A1 (en) 2000-03-15
AU7594498A (en) 1998-12-30
JP2002501532A (en) 2002-01-15
AU734009B2 (en) 2001-05-31

Similar Documents

Publication Publication Date Title
EG24412A (en) Novel compounds
DE69803272D1 (en) Hemmstoffe der stickstoffmonoxid-synthase
EG24177A (en) Novel compounds
ZA9811631B (en) Novel compounds
IL131661D0 (en) Protease inhibitors
GB9701684D0 (en) Novel compounds
PL340836A1 (en) Novel compounds
IL135248D0 (en) Novel combination
PL338518A1 (en) Novel compounds
IL132153D0 (en) Novel compounds
PL196471B1 (en) Substituted 3-cyanoquinolines
AP200001795A0 (en) Substituted 4-aminothiazol-2-yol
PL331338A1 (en) Thiosulphonamidic metaloprotease inhibitors
PL340261A1 (en) Substituted amilides
GB2321641B (en) Sulfamide-metalloprotease inhibitors
MX9803623A (en) Scale inhibitors
ZA9810249B (en) Novel substituted phenylketoenols
PL336589A1 (en) Serinic protease inhibitors
GR3036900T3 (en) Angiogenesis inhibiting pyridazinamines
IL132763D0 (en) Novel compounds
PL189418B1 (en) Novel phtalysinones
PL338452A1 (en) Novel substituted 6-phenylphenatridines
IL136368D0 (en) Novel compounds
ZA9800376B (en) Sulfamide-metalloprotease inhibitors
PL336039A1 (en) Novel compounds

Legal Events

Date Code Title Description
17P Request for examination filed

Effective date: 19991230

AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Despatch of supplementary search report

Effective date: 20010108

AK Designated contracting states:

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Classification (correction)

Free format text: 7A 01N 43/54 A, 7C 07D 487/04 B, 7A 61K 31/305 B, 7C 07D 487/04 J, 7C 07D 239:00 J, 7C 07D 231:00 J

17Q First examination report

Effective date: 20021022

18D Deemed to be withdrawn

Effective date: 20040224